GlassScriptPhysician profile
James W Tieman
NPI 1831173038
$9,794.65
in general payments reported to CMS, 2019-2025
55 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $903 · 2021: $2,181 · 2022: $1,458 · 2023: $2,045 · 2024: $1,282 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,353.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $961.62 | 2019-2025 | Jardiance, Ofev |
| Novo Nordisk INC | $922.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $900.00 | 2021-2024 | Vraylar |
| Glaxosmithkline, LLC. | $866.21 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $795.58 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $586.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $544.38 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $517.12 | 2019-2025 | Evenity, Prolia, Otezla |
| Novartis Pharmaceuticals Corporation | $319.34 | 2019-2023 | |
| Astellas Pharma US INC | $292.97 | 2019-2024 | Myrbetriq, Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $270.76 | 2019-2022 | |
| Dermira, INC. | $210.59 | 2020 | |
| Abbott Laboratories | $176.56 | 2021-2025 | Freestyle Libre 3 |
| Allergan, INC. | $174.10 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.88 | 2021-2025 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tieman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.